Buy & Sell Global X Defense Tech ETF (SHLD) – Global X Defense Tech ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Sector/ThematicSector
- -20.1%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 13 daysTypical Hold Time
Over the past 52 weeks, Global X Defense Tech ETF has traded between a low of $56.61 and a high of $78.02, highlighting its annual price range. Over the past three months, Global X Defense Tech ETF has recorded a drawdown of -20.1%, reflecting recent price volatility. On average, investors hold Global X Defense Tech ETF for approximately 13 days, indicating typical investor behavior on the platform.
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Most Recent News
Janus Henderson's JABS ETF offers high-yield, quality asset-backed securities with strong risk-adjusted returns.
Janus Henderson's Asset-Backed Securities ETF (JABS) actively invests in high-quality asset-backed securities (ABS) that typically yield more than traditional bonds with similar credit risk and duration. These securities provide attractive risk-adjus...

Korea Fund trades at 12% discount despite tech-driven gains, signaling potential buy opportunity.
The Korea Fund Inc (KF) offers investors exposure to South Korean equities, heavily weighted in tech giants Samsung and SK Hynix, which make up nearly 40% of the fund. Despite Korean stocks doubling in value this year and KF mirroring the performance...

Phase III trial shows sacituzumab tirumotecan plus pembrolizumab improves survival in first-line NSCLC treatment
Sichuan Kelun-Biotech announced positive Phase III trial results for sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab as first-line treatment for PD-L1 positive non-small cell lung cancer (NSCLC). The combination significantly extended p...
